My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 686 / https://doi.org/10.3332/ecancer.2016.686

Special Issue

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership.

Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.

Keywords: Health Technology Assessment, collaboration, innovations, oncology practice

Loading Article Metrics ... Please wait

Related articles

Case Report: Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis

Abstract | Full Article | PDF Published: 22 May 2018 / https://doi.org/10.3332/ecancer.2018.837

Short Communication: Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica

Abstract | Full Article | PDF Published: 24 Apr 2018 / https://doi.org/10.3332/ecancer.2018.829

Review: The current state of prostate cancer treatment in Trinidad and Tobago

Abstract | Full Article | PDF Published: 24 Apr 2018 / https://doi.org/10.3332/ecancer.2018.828

Research: Evidence on the cost of breast cancer drugs is required for rational decision making

Abstract | Full Article | PDF Published: 16 Apr 2018 / https://doi.org/10.3332/ecancer.2018.825

Clinical Study: Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents

Abstract | Full Article | PDF Published: 11 Apr 2018 / https://doi.org/10.3332/ecancer.2018.824



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence